The global plasma protein system market size is expected to reach US$ 25.7 Billion in 2022 and US$ 28.4 Billion in 2032. It is anticipated to exhibit growth at a steady CAGR of 6.2% in the forecast period from 2022 to 2032. The increasing demand for innovative therapeutic options and the surging approval of several plasma products worldwide are set to propel the sales of plasma protein systems.
| Report Attribute | Details |
| Plasma Protein System Market Estimated Base Year Value (2021) | US$ 24.1 Billion |
| Plasma Protein System Market Expected Market Value (2022) | US$ 25.7 Billion |
| Plasma Protein System Market Anticipated Forecast Value (2032) | US$ 28.4 Billion |
| Plasma Protein System Market Projected Growth Rate (2022-2032) | 6.2% CAGR |
Plasma protein, also known as blood protein, is a type of protein that is present in blood plasma. It serves various functions, such as the transportation of minerals, vitamins, hormones, and lipids in the body to maintain one’s immune system. It also acts as a kinin precursor, complement component, and an enzyme.
The rising usage of plasma proteins in replacement therapies to treat several conditions, including the deficiency of a coagulation factor during hemostasis is expected to propel the market. The increasing focus of many key players on the development of new systems that have enhanced efficacy is another crucial factor that is set to accelerate the market.
The ongoing development of innovative plasma extraction techniques and the surging prevalence of neuropathic pain and post-polio syndrome are anticipated to spur the demand for plasma protein systems. The rising demand for albumin in Asia Pacific for the treatment of sepsis, liver disease, Alzheimer’s disease, and malaria is also likely to drive the market.
High life expectancy and improved standard of living are expected to drive the geriatric population across the globe. It is further anticipated to result in favorable reimbursement policies and technological advancements in the healthcare sector.
The increasing prevalence of neurological and cardiovascular disorders among the geriatric population is likely to augur well for the global plasma protein system market growth in the evaluation period. According to the Pan American Health Organization (PAHO), around 533,172 deaths occurred in 2019 in the Region of the Americas due to neurological conditions. This number is projected to grow in the near future, thereby boosting the global market.
The lack of favorable reimbursement policies, especially in emerging economies is anticipated to hamper the growth in this market. In addition to that, the implementation of stringent norms by government bodies to control the handling of plasma protein products is expected to obstruct the growth. Plasma protein fractions can also lead to numerous side effects, such as hives, low blood pressure, fever, pulmonary edema, and anaphylaxis. This factor may hinder the growth in this market.
North America is estimated to remain at the forefront by generating the largest plasma protein system market share in the future years. This growth is attributable to the availability of a well-established infrastructure to maintain and store premium-quality plasma in the U.S.
Besides, the rising adoption of cutting-edge therapeutics and the presence of a large patient base in the U.S. are some of the other factors that are set to fuel the market. The increasing prevalence of numerous life-threatening diseases and the surging geriatric population are also projected to bode well for the North America market.
Asia Pacific is likely to showcase the fastest CAGR in the assessment period owing to the increasing usage of albumin in China. The rising per capita income of people and the growing need for state-of-the-art treatment options in India are estimated to bolster the demand for plasma protein systems across Asia Pacific.
As per a research study published by the National Library of Medicine, since 2006, the prevalence of cardiovascular diseases has increased at a fast pace in China. Out of about 290 million patients with these diseases, 245 million, 13 million, and 4.5 million have hypertension, stroke, and heart failure, respectively. Thus, the surging prevalence of various diseases in developing countries of Asia Pacific is projected to drive the market.
Some of the renowned companies operating in the global plasma protein system market are Octapharma USA Inc., CSL Behring, Takeda Pharmaceutical Company Ltd., Grifols SA, Baxter, Biotest AG, and China Biologic Products, Inc. among others.
Majority of the key players are engaging in research and development activities to come up with novel products to gain fast track approvals from regulatory bodies. The market is highly competitive with the presence of many large- and small-scale companies that are increasingly focusing on broadening their plasma collection networks. Meanwhile, a few other companies are aiming to surge their market share by conducting clinical trials and expanding their geographic presence.
| Report Attribute | Details |
| Growth Rate | CAGR of 6.2% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Product Type:
By Application:
By End User:
By Region:
The global plasma protein system market is estimated to surpass US$ 28.4 Billion till 2032.
North America is likely to dominate the plasma protein system market.
Octapharma USA Inc., CSL Behring, Takeda Pharmaceutical Company Ltd., Grifols SA, Baxter, Biotest AG, and China Biologic Products, Inc. are some of the leading plasma protein system manufacturers.
Explore Similar Insights
Plasma Protein System Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
